271 related articles for article (PubMed ID: 10598789)
1. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPgammaS binding.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):500-9. PubMed ID: 10598789
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):522-32. PubMed ID: 10598791
[TBL] [Abstract][Full Text] [Related]
3. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):510-21. PubMed ID: 10598790
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Siehler S; Seuwen K; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):488-99. PubMed ID: 10598788
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features.
Siehler S; Zupanc GK; Seuwen K; Hoyer D
Neuropharmacology; 1999 Mar; 38(3):449-62. PubMed ID: 10219983
[TBL] [Abstract][Full Text] [Related]
7. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S; Seuwen K; Hoyer D
Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of the goldfish somatostatin sst5 receptor.
Nunn C; Feuerbach D; Lin X; Peter R; Hoyer D
Eur J Pharmacol; 2002 Feb; 436(3):173-86. PubMed ID: 11858797
[TBL] [Abstract][Full Text] [Related]
9. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.
Cervia D; Fehlmann D; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):578-87. PubMed ID: 12750875
[TBL] [Abstract][Full Text] [Related]
10. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.
Nunn C; Schoeffter P; Langenegger D; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):1-9. PubMed ID: 12616335
[TBL] [Abstract][Full Text] [Related]
11. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery.
Fehlmann D; Langenegger D; Schuepbach E; Siehler S; Feuerbach D; Hoyer D
J Physiol Paris; 2000; 94(3-4):265-81. PubMed ID: 11088004
[TBL] [Abstract][Full Text] [Related]
12. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterisation of human cerebral cortex somatostatin SRIF1 and SRIF2 receptors.
Piwko C; Thoss VS; Schüpbach E; Kummer J; Langenegger D; Probst A; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):161-7. PubMed ID: 9050007
[TBL] [Abstract][Full Text] [Related]
14. [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Siehler S; Seuwen K; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1998 May; 357(5):483-9. PubMed ID: 9650799
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin5 receptor-mediated [35S]guanosine-5'-O-(3-thio)triphosphate binding: agonist potencies and the influence of sodium chloride on intrinsic activity.
Williams AJ; Michel AD; Feniuk W; Humphrey PP
Mol Pharmacol; 1997 Jun; 51(6):1060-9. PubMed ID: 9187273
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptors in the rhesus monkey brain: localization and pharmacological characterization.
Thoss VS; Piwko C; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):648-60. PubMed ID: 8738298
[TBL] [Abstract][Full Text] [Related]
17. Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells.
Castro SW; Buell G; Feniuk W; Humphrey PP
Br J Pharmacol; 1996 Feb; 117(4):639-46. PubMed ID: 8646408
[TBL] [Abstract][Full Text] [Related]
18. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
19. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Feuerbach D; Fehlmann D; Nunn C; Siehler S; Langenegger D; Bouhelal R; Seuwen K; Hoyer D
Neuropharmacology; 2000 Jun; 39(8):1451-62. PubMed ID: 10818261
[TBL] [Abstract][Full Text] [Related]
20. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
